Expression of serum miR-16, let-7f, and miR-21 in patients with hepatocellular carcinoma and their clinical significances

Clinical Laboratory

Volumn 60, Issue 3, 2014, Pages 427-434

  Ge, Wei ^a,b   Yu, De Cai ^a,b   Li, Qing Guo ^b   Chen, Xi ^b   Zhang, Chen Yu ^b   Ding, Yi Tao ^a,b  

^a NANJING MEDICAL UNIVERSITY   (China)

^b NANJING UNIVERSITY   (China)

Author keywords

Biomarker; Diagnosis; Hepatocellular carcinoma; MicroRNA; Sera

Indexed keywords

ALPHA FETOPROTEIN; BILIRUBIN; BIOLOGICAL MARKER; LET 7F PROTEIN; MICRORNA; MICRORNA 16; MICRORNA 21; MICRORNA 221; MICRORNA 98; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER SIZE; CLINICAL FEATURE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE EXPRESSION; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THROMBOCYTE; UPREGULATION;

CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MICRORNAS; MIDDLE AGED; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL;

EID: 84896445385     PISSN: 14336510     EISSN: None     Source Type: Journal    
DOI: 10.7754/Clin.Lab.2013.130133     Document Type: Article

References (30)

1. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007,132(7):2557-76. (Pubitemid 46890874)
2. Benson AB, 3rd, Abrams TA, Ben-Josef E, et al. NCCN clinical practice guidelines in oncology: hepatobiliary cancers. J Natl Compr Canc Netw 2009,7(4):350-91.
3. Ambros V. The functions of animal microRNAs. Nature 2004,431(7006):350-5. (Pubitemid 39265675)
4. Kloosterman WP, Plasterk RH. The diverse functions of microRNAs in animal development and disease. Dev Cell 2006,11(4):441-50. (Pubitemid 44430905)
5. Stefani G, Slack FJ. Small non-coding RNAs in animal development. Nat Rev Mol Cell Biol 2008,9(3):219-30. (Pubitemid 351301826)
6. Zamore PD, Haley B. Ribo-gnome: the big world of small RNAs. Science 2005,309(5740):1519-24. (Pubitemid 41266468)
7. Meister G. miRNAs get an early start on translational silencing. Cell 2007,131(1):25-8. (Pubitemid 47498539)
8. Fornari F, Gramantieri L, Ferracin M, et al. MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma. Oncogene 2008,27(43):5651-61.
9. Medina R, Zaidi SK, Liu CG, et al. MicroRNAs 221 and 222 bypass quiescence and compromise cell survival. Cancer Res 2008,68(8):2773-80. (Pubitemid 351556275)
10. Kim S, Lee UJ, Kim MN, et al MicroRNA miR-199a*regulates the MET proto-oncogene and the downstream extracellular signal-regulated kinase 2 (ERK2). J Biol Chem 2008,283(26):18158-66.
11. Gramantieri L, Ferracin M, Fomari F, et al. Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. Cancer Res 2007,67(13):6092-9. (Pubitemid 47037488)
12. Xi Y, Nakajima G, Gavin E, Morris CG, Kudo K, Hayashi K, Ju J: Systematic analysis of microRNA expression of RNA extracted from fresh frozen and formalin-fixed paraffin-embedded samples. RNA 2007,13(10):1668-1674. (Pubitemid 47481675)
13. Chen X, Ba Y, Ma L, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008,18(10):997-1006.
14. Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 2008,105(30):10513-8.
15. Li A, Omura N, Hong SM, et al Pancreatic cancers epigenetically silence S1P1 and hypomethylate and overexpress miR-200a/200b in association with elevated circulating miR-200a and miR-200b levels. Cancer Res 2010,70(13):5226-37.
16. Tsujiura M, Ichikawa D, Komatsu S, et al. Circulating microRNAs in plasma of patients with gastric cancers. Br J Cancer 2010,102(7):1174-9.
17. Miyachi M, Tsuchiya K, Yoshida H, et al. Circulating muscle-specific microRNA, miR-206, as a potential diagnostic marker for rhabdomyosarcoma. Biochem Biophys Res Commun 2010,400(1):89-93.
18. Qu KZ, Zhang K, Li H, Afdhal NH, Albitar M. Circulating microRNAs as biomarkers for hepatocellular carcinoma. J Clin Gastroenterol 2011,45(4):355-60.
19. Li LM, Hu ZB, Zhou ZX, et al. Serum microRNA profiles serve as novel biomarkers for HBV infection and diagnosis of HBV-positive hepatocarcinoma. Cancer Res 2010,70(23):9798-807.
20. Sukata T, Sumida K, Kushida M, et al. Circulating microRNAs, possible indicators of progress of rat hepatocarcinogenesis from early stages. Toxicol Lett 2011,200(1-2):46-52.
21. Li J, Wang Y, Yu W, Chen J, Luo J. Expression of serum miR-221 in human hepatocellular carcinoma and its prognostic significance. Biochem Biophys Res Commun 2011,406(1):70-3.
22. Yamamoto Y, Kosaka N, Tanaka M, et al. MicroRNA-500 as a potential diagnostic marker for hepatocellular carcinoma. Biomarkers 2009,14(7):529-38.
23. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 2008,3(6):1101-1108. (Pubitemid 351818697)
24. Chen C, Ridzon DA, Broomer AJ, et al. Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res 2005,33(20):e179.
25. Sukata T, Sumida K, Kushida M, et al. Circulating microRNAs, possible indicators of progress of rat hepatocarcinogenesis from early stages. Toxicol Lett 2011,200(1-2):46-52.
26. Zhou J, Yu L, Gao X, et al. Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma. J Clin Oncol 2011,29(36):4781-8.
27. Xu J, Wu C, Che X, et al. Circulating microRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis. Mol Carcinog 2011,50(2):136-42.
28. Wang F, Zheng Z, Guo J, Ding X. Correlation and quantitation of microRNA aberrant expression in tissues and sera from patients with breast tumor. Gynecol Oncol 2010,119(3):586-93.
29. Rabinowits G, Gercel-Taylor C, Day JM, Taylor DD, Kloecker GH. Exosomal microRNA: a diagnostic marker for lung cancer. Clin Lung Cancer 2009,10(1):42-6.
30. Giordano S, Columbano A. MicroRNAs: new tools for diagnosis, prognosis, and therapy in hepatocellular carcinoma? Hepatology 2013,57(2):840-7.